In this episode of “Blood Cancer Talks,” Rakesh Popat, MBBS, MRCP, RCDPath, PhD, of University College London Hospitals NHS Foundation Trust, joins hosts Raj Chakraborty, MD, and Ashwin Kishtagari, MD, to highlight multiple myeloma (MM) updates from the 66th American Society of Hematology Annual Meeting & Exposition.
Drs. Popat, Chakraborty, and Kishtagari discuss the AQUILA trial of daratumumab in high-risk smoldering MM, the iMMagine-1 trial of anitocabtagene autoleucel in relapsed or refractory MM, the CARTITUDE-4 trial of ciltacabtagene autoleucel in lenalidomide-refractory MM, and more.
Finally, Dr. Popat and the hosts conclude their discussion with a rundown of novel agents such as inobrodib and cevostamab.